Literature DB >> 8223835

The disposition of paracetamol and its conjugates during multiple dosing in patients with end-stage renal failure maintained on haemodialysis.

U Martin1, R M Temple, R J Winney, L F Prescott.   

Abstract

The disposition of oral paracetamol (1.0 g 3 times daily for 10 days) was studied in 6 patients with end-stage renal failure (creatinine clearance < 5 ml x min-1) maintained on haemodialysis 2 or 3 times per week. Blood was sampled daily for 10 days. The time of sampling depended on whether the patients were dialysed in the morning or afternoon but was always within 5 h of the last dose of paracetamol. On dialysis days samples were taken at the start of the session. The mean plasma concentration of paracetamol was 6.8 mg x l-1 after the first 24 h and subsequently varied little throughout the 10 days. Apparent steady-state plasma concentrations of 60.0 mg x l-1 and 54.5 mg x l-1 were reached for the glucuronide and sulphate conjugate of paracetamol respectively by the 2nd day of treatment with little variation throughout the remainder of the study. These steady-state concentrations of paracetamol glucuronide and sulphate were much lower than predicted. The steady-state plasma concentrations of the retained cysteine and mercapturate conjugates of paracetamol were low (5.7 and 3.7 mg x l-1, respectively) and there was no evidence of accumulation of these potentially toxic metabolites. It is not clear why regular dosing with paracetamol in haemodialysis patients did not cause the accumulation of paracetamol glucuronide or sulphate as predicted. There may be enterohepatic elimination of retained paracetamol conjugates or depletion of substrates such as inorganic sulphate during chronic dosing.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8223835     DOI: 10.1007/bf00315495

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Effect of hemodialysis on kinetics of acetaminophen elimination by anephric patients.

Authors:  S Oie; D T Lowenthal; W A Briggs; G Levy
Journal:  Clin Pharmacol Ther       Date:  1975-12       Impact factor: 6.875

2.  Studies on sulfate in end-stage renal disease.

Authors:  R M Freeman; C J Richards
Journal:  Kidney Int       Date:  1979-02       Impact factor: 10.612

3.  Biliary excretion of acetaminophen in ureter-ligated rats.

Authors:  C P Siegers; C D Klaassen
Journal:  Pharmacology       Date:  1984       Impact factor: 2.547

Review 4.  Paracetamol overdosage. Pharmacological considerations and clinical management.

Authors:  L F Prescott
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546

Review 5.  Drug metabolites in renal failure: pharmacokinetic and clinical implications.

Authors:  R K Verbeeck; R A Branch; G R Wilkinson
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

6.  Sulfate depletion after acetaminophen administration and replenishment by infusion of sodium sulfate or N-acetylcysteine in rats.

Authors:  J H Lin; G Levy
Journal:  Biochem Pharmacol       Date:  1981-10-01       Impact factor: 5.858

7.  Dose- and time-dependent elimination of acetaminophen in rats: pharmacokinetic implications of cosubstrate depletion.

Authors:  R E Galinsky; G Levy
Journal:  J Pharmacol Exp Ther       Date:  1981-10       Impact factor: 4.030

8.  The disposition of paracetamol and the accumulation of its glucuronide and sulphate conjugates during multiple dosing in patients with chronic renal failure.

Authors:  U Martin; R M Temple; R J Winney; L F Prescott
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  The effect of acetaminophen administration on its disposition and body stores of sulphate.

Authors:  S Hendrix-Treacy; S M Wallace; K W Hindmarsh; G M Wyant; A Danilkewich
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Paracetamol disposition and metabolite kinetics in patients with chronic renal failure.

Authors:  L F Prescott; G C Speirs; J A Critchley; R M Temple; R J Winney
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

View more
  4 in total

1.  Physiologically based modeling of the pharmacokinetics of acetaminophen and its major metabolites in humans using a Bayesian population approach.

Authors:  Todd J Zurlinden; Brad Reisfeld
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-01-31       Impact factor: 2.441

2.  Acetaminophen clearance during ex vivo continuous renal replacement therapies.

Authors:  Bridget A Scoville; Vera Vulaj; Bruce A Mueller; Gail M Annich; Deborah S Wagner
Journal:  J Artif Organs       Date:  2017-10-23       Impact factor: 1.731

Review 3.  Assessing and Treating Chronic Pain in Patients with End-Stage Renal Disease.

Authors:  Flaminia Coluzzi
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

4.  Identification of the cerebral effects of paracetamol in healthy subjects: an fMRI study.

Authors:  Olivier De Coster; Patrice Forget; Johan De Mey; Peter Van Schuerbeek; Jan Poelaert
Journal:  Br J Pain       Date:  2019-06-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.